Immunotherapy and PARP inhibitor combo tested in Hard-to-Treat breast cancer
Disease control
Completed
This small pilot study tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the PARP inhibitor olaparib (Lynparza) can shrink tumors in people with advanced BRCA-mutated breast cancer. Fourteen participants whose cancer had progressed after prior treatmen…
Phase: PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC